IFP Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

IFP Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$12	–	5024
2025 Q4	$12	Hold	1	–	–	﹤0.01%	4831
2025 Q3	$14	Buy	+1	New	+$9	﹤0.01%	4771

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

IFP Advisors's AMLX Position: Q1 2026 in Review

IFP Advisors sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 1 share — an estimated $12 sold.

IFP Advisors first reported a position in AMLX in Q3 2025 and held it in 2 quarters. The position peaked at $14 in Q3 2025. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

IFP Advisors reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
IFP Advisors sold 1 Amylyx Pharmaceuticals share in Q1 2026, an estimated $12.
IFP Advisors first reported a position in Amylyx Pharmaceuticals in Q3 2025 and held it in 2 quarters.
IFP Advisors's Amylyx Pharmaceuticals position peaked at $14 in Q3 2025.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on IFP Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.